6.97
-0.3(-4.13%)
Currency In USD
| Previous Close | 7.27 |
| Open | 7.11 |
| Day High | 7.4 |
| Day Low | 6.92 |
| 52-Week High | 17.41 |
| 52-Week Low | 2.24 |
| Volume | 481,114 |
| Average Volume | 1.14M |
| Market Cap | 325.49M |
| PE | -1.97 |
| EPS | -3.53 |
| Moving Average 50 Days | 5.36 |
| Moving Average 200 Days | 4.87 |
| Change | -0.3 |
If you invested $1000 in 4D Molecular Therapeutics, Inc. (FDMT) since IPO date, it would be worth $172.1 as of September 08, 2025 at a share price of $6.97. Whereas If you bought $1000 worth of 4D Molecular Therapeutics, Inc. (FDMT) shares 3 years ago, it would be worth $739.92 as of September 08, 2025 at a share price of $6.97.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
4DMT Announces Leadership Expansion with Proven Late-Stage Executives to Drive 4D-150 Execution and BLA Readiness
GlobeNewswire Inc.
Sep 02, 2025 12:00 PM GMT
Julie Clark, M.D., promoted to Chief Medical Officer Liansheng Zhu, Ph.D., joined as SVP, Biometrics and Data Quality4FRONT-1 Phase 3 trial enrollment continues to exceed expectations, with enrollment completion now expected in Q1 2026 Addition of di
4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
GlobeNewswire Inc.
Aug 06, 2025 12:00 PM GMT
EMERYVILLE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatmen
4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update
GlobeNewswire Inc.
Jul 31, 2025 8:05 PM GMT
4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level4D-150 demonstrated durable and dose-dependent clinical activity with sustained gains in visual acuity and anatomic control Phase 3 dose (3E